Healthcare

L’Oréal’s tardy skin care facelift may backfire

5 Aug 2024

After sitting out its IPO, the cosmetics giant is buying 10% of $19 bln dermatology specialist Galderma, which it sold in 2014. The Swiss firm’s fast-growing injectable business is attractive. Yet the move risks making a potential full takeover overly expensive.

Philips’ share-price revival is only half finished

29 Jul 2024

The Dutch medical group’s orders are finally growing again, boosting the stock by 10%. Yet Philips is still well below its 2021 peak, before a faulty sleep-aid crisis. Keeping margins high and sales rising may help, but selling the consumer unit may complete the rejuvenation.

Novo Nordisk obesity feast no longer a free lunch

18 Jul 2024

The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.

Ozempic may gift US a $3 trln benefit

16 Jul 2024

Tech advances are the unpredictable joker of healthcare spending, sometimes adding to outlays. Recent estimates to the United States' medical bill suggest costs will rise, even with the new obesity drug. But previous technological advances in medicine have been underestimated.

Drugmaker’s US listing journey starts with failure

9 Jul 2024

Shares in $2 bln Indivior, which in June switched its primary venue from London to New York, fell 42% after flagging slower opioid-treatment sales. Investors may fear that CEO Mark Crossley took his eye off the ball. With little broker coverage, it risks becoming an orphan stock.

Smith & Nephew faces long and painful activist fix

4 Jul 2024

Cevian has taken a 5% stake in the $11 bln underperforming London-listed medical equipment maker. Curing its depressed share price will require deep operational surgery. While that may take time, a breakup could be a second treatment further down the line.

Moderna stock is lone omen of bird flu pandemic

17 Jun 2024

The $56 bln Covid vaccine maker’s stock is up 40% since March after an avian flu outbreak. A new jab might be worth trillions for society. The uncertainty about another pestilence, however, means its value to Moderna is probably less than what investors have already gained.

Investors prescribe harsh medicine for GSK’s boss

3 Jun 2024

Shareholders wiped $9 bln off the UK drugmaker’s market value after a US judge approved lawsuits over heartburn drug Zantac. It may be an overreaction given the company’s win in another state and previous settlements. But it adds pressure on CEO Emma Walmsley’s turnaround plan.

Precision-medicine IPO deserves Groupon discount

31 May 2024

Tempus helps tailor treatments with its library of DNA and other tests. In a market giddy about AI, it could be worth $6 bln. One hitch is that founder Eric Lefkofsky, who started the online coupon provider, will keep control. The marginal value of its data is also shrinking.

AI will help treat Big Pharma’s looming illness

15 May 2024

Drug discovery is a long and costly process with success rates below 10%. Caps on prices and shorter patent periods in the US will also make life harder for the likes of Pfizer, AstraZeneca and rivals. Despite patchy results, betting on machines may be the best hope of a cure.

Memo to McKinsey: Avoiding Arthur Andersen’s fate

14 May 2024

After coughing up $1 bln for opioid-related settlements, the elite consultant may face criminal charges, too. There are notable differences from when a 2002 US indictment killed the auditing giant. But the looming existential threat increases the likelihood of costly concessions.

The Agnellis’ risky Philips bet starts to pay off

29 Apr 2024

The Dutch group settled its US faulty sleeping aid claims for a manageable $1.1 bln, lifting its stock 35%. The relatively quick fix vindicates Exor CEO John Elkann’s $3 bln punt on Philips when legal worries kept investors away. It may also shift the thinking on big litigations.

UnitedHealth shows market power is double-edged

16 Apr 2024

The insurer’s reach in the US healthcare system drew an antitrust probe – and a ransomware attack that could cost $1.6 bln. It’s grist for trustbusters: dominance may let firms take their eye off the ball on cybersecurity, and make the systems that depend on them more fragile.

Capital Calls: Philips

10 Apr 2024

Concise views on global finance: The Dutch company’s CEO Roy Jakobs secured a win by finalising a settlement with US regulators over faulty sleep aids. But myriad other potentially costly cases remain open, justifying an ongoing share-price discount.

Blackstone cures two ailments in one Moderna shot

27 Mar 2024

Higher costs of capital are pressuring CEOs into tough spending decisions, while buyout shops flush with cash want to deploy it. This dynamic makes a $750 mln deal to fund a biotech project a crafty solution. The hard end of the bargain: ceding value from promising flu research.

Capital Calls: Wegovy gets a booster

22 Mar 2024

Concise views on global finance: The US government’s decision to pay for weight-loss drugs for some older patients is a big step for makers Eli Lilly and Novo Nordisk. Not because it will boost their share prices, but because it makes current valuations less far-fetched.

European private equity IPO door is only half open

22 Mar 2024

Buyout firms tested the market with cautious pricing for two beauty companies’ listings. Although Galderma performed, Douglas’s debt pile spooked investors. For sellers sitting on $3 trln of unsold assets the message is clear: discounts work, but only for healthy businesses.

Reckitt slump offers a cue to slim down

18 Mar 2024

The $41 bln Lysol maker’s shares fell sharply after it lost a US court case. One option for Reckitt Benckiser is to separate the nutrition arm, focus of the legal woes. That would ease the hit to the rest of the group, but also leave a new arm that may yet be worth something.

American healthcare is a perfect cyber-hostage

7 Mar 2024

A hack at the biggest processor of insurance claims snarled billions of dollars of payments to US hospitals. The healthcare system’s interdependent web of middlemen means none can be allowed to fail, making it an ever-more-obvious target for the growing onslaught of ransomware.

Galderma IPO offers EQT a temporary facelift

6 Mar 2024

The Swiss skin care group is looking to raise $2 bln in a listing to cut debt. At $22 bln, in line with L’Oréal’s valuation, its private equity owners could get decent returns. But with the French beauty giant growing similar products faster, retaining margins may be challenging.